Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, December 2, 2022
[ Fri, Dec 02nd 2022
] - WOPRAI
[ Fri, Dec 02nd 2022
] - WOPRAI
[ Fri, Dec 02nd 2022
] - WOPRAI
[ Fri, Dec 02nd 2022
] - WOPRAI
[ Fri, Dec 02nd 2022
] - WOPRAI
[ Fri, Dec 02nd 2022
] - WOPRAI
[ Fri, Dec 02nd 2022
] - WOPRAI
[ Fri, Dec 02nd 2022
] - WOPRAI
[ Fri, Dec 02nd 2022
] - WOPRAI
[ Fri, Dec 02nd 2022
] - WOPRAI
[ Fri, Dec 02nd 2022
] - WOPRAI
[ Fri, Dec 02nd 2022
] - WOPRAI
[ Fri, Dec 02nd 2022
] - WOPRAI
[ Fri, Dec 02nd 2022
] - WOPRAI
[ Fri, Dec 02nd 2022
] - WOPRAI
Thu, December 1, 2022
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
Corinne Jenkins Upgraded (BTAI) to Hold and Held Target at $16 on, Dec 1st, 2022
Corinne Jenkins of Goldman Sachs, Upgraded "BioXcel Therapeutics, Inc." (BTAI) to Hold and Held Target at $16 on, Dec 1st, 2022.
Corinne has made no other calls on BTAI in the last 4 months.
There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 0 agree with Corinne's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Corinne
- Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Decreased Target to $18 on, Wednesday, November 16th, 2022
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $76 on, Friday, November 11th, 2022
- Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $25 on, Friday, November 11th, 2022
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $85 on, Wednesday, August 24th, 2022
